



(51) International Patent Classification:

C07K 16/28 (2006.01) A61P 35/00 (2006.01)  
C07K 16/30 (2006.01) A61K 39/395 (2006.01)

(21) International Application Number:

PCT/US2025/014779

(22) International Filing Date:

06 February 2025 (06.02.2025)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/550,898 07 February 2024 (07.02.2024) US

(71) Applicant: **REGENERON PHARMACEUTICALS, INC.** [US/US]; 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US).

(72) Inventors: **INGHAM, Matthew**; c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **MILLER, Elizabeth**; c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **SEEBACH, Frank**; c/o

Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US).

(74) Agent: **TERMES, Lance A.**; Schwabe, Williamson & Wyatt PC, 1211 SW 5th Ave., Suite 1900, Portland, Oregon 97204 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,

(54) Title: METHODS OF TREATING PROSTATE CANCER WITH BISPECIFIC ANTI-PSMA X ANTI-CD3 ANTIBODIES AND BISPECIFIC ANTI-PSMA X ANTI-CD28 ANTIBODIES

Low Dose REGN4336 in Combination with REGN5678 Inhibits  
TRAMP2/hPSMA Tumor Growth in PSMA/CD3/CD28-Humanized Mice




FIG. 1

(57) Abstract: The present disclosure provides methods for treating, reducing the severity, or inhibiting the growth of a PSMA-expressing cancer (e.g., prostate cancer or metastatic castration-resistant prostate cancer). The methods of the present disclosure comprise administering to a subject in need thereof a bispecific anti-PSMA x CD3 antibody as monotherapy or in combination with an anti-PD-1 antibody or a bispecific anti-PSMA x anti-CD28 antibody.

[Continued on next page]



LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,  
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,  
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

**Published:**

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*